Evolocumab's LDL Lowering Surpassed Inclisiran's in ORION-3

Results from a crossover subgroup of 92 patients in ORION-3 documented evolocumab's greater LDL-lowering efficacy compared with inclisiran.
MDedge News

source https://www.medscape.com/viewarticle/987120?src=rss